Eberconazole

Drug Profile

Eberconazole

Alternative Names: Eberconazol; Eberconazole nitrate; Ebernet; WAS 2160

Latest Information Update: 08 Nov 2010

Price : $50

At a glance

  • Originator Chiesi Wassermann
  • Developer Chiesi Wassermann; SALVAT
  • Class Antifungals; Cycloheptanes; Imidazoles; Small molecules
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Mycoses; Tinea

Most Recent Events

  • 05 Sep 2007 Launched for Tinea in India (Topical)
  • 05 Sep 2007 Launched for Mycoses in India (Topical)
  • 31 Dec 2006 Eberconazole is available for licensing in European countries other than Spain (http://www.salvat-lab.es)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top